Leggi la pubblicazione completa in PDF
Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs …
Autori
Valentina Ceserani, Anna Ferri, Angiola Berenzi, Anna Benetti, Emilio Ciusani, Luisa Pascucci, Cinzia Bazzucchi, Valentina Coccè, Arianna Bonomi, Augusto Pessina, Erica Ghezzi, Offer Zeira, Piero Ceccarelli, Silvia Versari, Carlo Tremolada, Giulio Alessandri
